OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
February 25, 2021
The companies will integrate Welldoc’s digital insulin management solution, BlueStar, into Eli Lilly’s connected insulin solutions.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.
The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.
February 15, 2021
4D pharma has signed a clinical trial collaboration and supply agreement with Merck and Pfizer for Bavencio (avelumab).
February 12, 2021
Exscientia has formed a partnership with the ARUK-ODDI for the development of medicines targeting neuroinflammation to treat Alzheimer’s disease.
February 10, 2021
The cell therapy will be manufactured for each individual patient at BMS’ immunotherapy manufacturing facility in Bothell, WA, and will be launched across a network of treatment centers.
The companies will build capacity in Germany that will be ready in 2022 and are exploring options for increasing volume in 2021.
Through the agreement, AbbVie will use Caribou’s next-generation Cas12a CRISPR hybrid RNA–DNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies.
February 04, 2021
The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.
February 03, 2021
As demand for COVID-19 vaccines increases, Big Pharma offers its manufacturing capacity and expertise.
January 29, 2021
The vaccine is 66% effective overall in preventing moderate to severe COVID-19 28 days after vaccination.
The vaccine met the primary endpoint with a vaccine efficacy of 89.3% in its Phase III trial in the United Kingdom and a vaccine efficacy of 49% in HIV-positive participants and 60% in HIV-negative participants in a South African Phase IIb trial.
January 28, 2021
Evozyne’s evolution-based protein design technology will be used to research and develop proteins that could be used in the next generation of gene therapies.
January 25, 2021
The company is discontinuing the development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, to focus on advancing its two SARS-CoV-2/COVID-19 therapeutic candidates, MK-4482 and MK-7110.
January 22, 2021
The drug offers immediate post-exposure protection against the virus and will serve as a counterpart to the vaccine during its early phases.
January 20, 2021
Through the acquisition, Thermo Fisher will have access to Mesa’s PCR-based rapid point-of-care testing platform for detecting infectious diseases.
January 15, 2021
This new agreement covers 1.25 million additional doses of the antibody cocktail containing casirivimab and imdevimab for the treatment of COVID-19.
The collaboration will focus on up to three types of lung and gastrointestinal cancers.
The first four investments of the new program will support clinical-stage biotechnology companies while new investments will include companies focused on oncology, rare disease, and inflammation and immunology.
January 07, 2021
Bayer will support the development and supply of CureVac’s COVID-19 vaccine candidate, CVnCoV.